Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 02 2022 - 08:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16
or 15d-16
Under the Securities Exchange Act of 1934
For the Month of May 2022
Commission File Number: 001-41084
NeuroSense Therapeutics Ltd.
(Translation of registrant’s name into English)
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-799-6183
(Address of principal executive office)
Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Company
Presentation
NeuroSense
Therapeutics Ltd. (the “Company”) has made available a presentation about its business (the “Presentation”),
a copy of which is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The furnishing of the Presentation is not an admission
as to the materiality of any information therein. The information contained in the Presentation is summary information that should be
considered in the context of the Company’s filings with the Ssecurities and Exchange Commission and other public announcements the
Company may make by press release or otherwise from time to time.
Exhibit Index
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
NeuroSense Therapeutics Ltd. |
|
|
|
Date: May 2, 2022 |
By: |
/s/ Alon Ben-Noon |
|
|
Alon Ben-Noon |
|
|
Chief Executive Officer |
3
NeuroSense Therapeutics (NASDAQ:NRSN)
Historical Stock Chart
From Feb 2024 to Mar 2024
NeuroSense Therapeutics (NASDAQ:NRSN)
Historical Stock Chart
From Mar 2023 to Mar 2024